
Please try another search
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Name | Age | Since | Title |
---|---|---|---|
Randy Wayne Schekman | 74 | - | Member of Scientific Advisory Board |
W. Michael Kavanaugh | 68 | - | Member of Scientific Advisory Board |
Hong Zhang | - | 2024 | Chairman |
Cheng Liu | 57 | - | CEO, President & Director |
Marsha Roberts | 53 | - | Independent Director |
Gianpietro Dotti | - | - | Member of Scientific Advisory Board |
Stephan A. Grupp | - | - | Member of Scientific Advisory Board |
Fan Wu | 50 | 2023 | Independent Director |
Pei Xu | 42 | 2023 | Independent Director |
Xuejun Wu | 50 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review